ClinicalTrials.gg
RecruitingNCT06487481Updated Nov 20, 2026

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

A Phase 1 interventional study of Surgical resection and Preoperative RT in Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC) and Recurrent Abdominal Adrenocortical Carcinoma (ACC), sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know

Updated Nov 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI) — 5 open to participants now, 8 under way, none of them phase 3. Adrenocortical Carcinoma · National Cancer Institute (NCI).

Planned enrollment
9th of 15
32 · median 42
Started
2026
with 2 others
Phase 1
5 of 18
3 open now
Registered
16th of 18
by date

Among the 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI), this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 1, and was the 16th registered.

Adrenocortical Carcinoma

94 studies on the registry are indexed under Adrenocortical Carcinoma; 26 are open to participants now.

Browse Adrenocortical Carcinoma studies →

Open to participants now

5 of the 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 21 Adrenocortical Carcinoma studies recruiting now, 15 (71%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Adrenocortical Carcinoma by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis.

Objective:

To test a new type of external beam RT before surgery in people with ACC.

Eligibility:

People aged 18 years and older with ACC that came back after treatment but may be safely removed with surgery.

Design:

Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have imaging scans. A small sample of tumor tissue may be collected if one is not available. They will undergo laparoscopy: Small incisions will be made in the abdomen so that a thin tube with a light and camera can be inserted to view the organs.

RT comes from a machine that aims radiation at tumors. Participants will receive preoperative RT in daily fractions over approximately 2-3 weeks, followed by a planned surgical resection about 4 weeks after the completion of RT. Visits will last 30 to 60 minutes.

Participants will undergo surgery to remove their tumors about 4 weeks after they finish RT. They will stay in the hospital 1 to 3 weeks after surgery.

Participants will have follow-up visits for 10 years after surgery.

Read the detailed description

Background:

  • Although surgical resection is the treatment of choice in participants with localized or regionalized primary and recurrent abdominal adrenocortical carcinoma (ACC), loco-regional recurrence following complete resection of ACC occurs in 50-80% of the participants, most commonly in the first five years postoperatively.
  • Retrospective single institutional series report improvement in local control with postoperative adjuvant radiotherapy (RT) in selected participants with ACC.
  • Preoperative RT is used in several abdominal and retroperitoneal malignancies to improve local control. There is no prospective data available for the use of this treatment approach for participants with resectable ACC.
  • We hypothesize that preoperative RT alone is safe and can result in a lower loco-regional recurrence in participants with resectable recurrent ACC with no peritoneal carcinomatosis. Thus, this phase I dose-escalation trial aims to evaluate the safety and feasibility of preoperative RT in participants with resectable recurrent ACC.
  • Health-related quality of life (QOL) is a well-accepted tool to measure the outcome of cancer treatments. SF-36 V1 questionnaire has been frequently used to evaluate the QOL in participants with cancer. There is no study evaluating the difference in QOL in participants with resectable recurrent ACC undergoing preoperative RT and surgery.

Objectives:

-To determine the maximum tolerated dose and the safety and toxicity profile of preoperative external beam RT with or without standard of care mitotane, before surgical resection in participants with resectable ACC

Eligibility:

  • Age >= 18 years
  • Pathological confirmation of ACC with clinical evidence of abdominal recurrence
  • ECOG 0-2
  • Surgically resectable disease at presentation with no or limited extra-abdominal disease and without ACC peritoneal carcinomatosis based on a diagnostic laparoscopy at screening.
  • The last dose of chemotherapy treatment except for mitotane more than 4 weeks prior to starting treatment with this protocol, and participants must have recovered from chemotherapy.
  • No prior abdominal RT
  • No contraindication to abdominal RT

Design:

  • This study will enroll up to 24 evaluable participants as follows:

    • Participants will be enrolled in Cohort 1 or 2 based on mitotane use or serum level. Up to 6-18 evaluable participants per these cohorts (i.e., resectable ACC with and without mitotane use) will be enrolled to assess the safety of 3-level dose-escalating preoperative RT.
    • Participants will be enrolled in Cohort 3 regardless of mitotane use or serum level, and will only start enrollment when we observe no DLTs in > 1 participant in Cohort 1 at Dose Level 1. Up to 12 evaluable participants will be enrolled in this cohort.
  • Preoperative assessment of QOL using a standardized questionnaire (SF-36 V1) will be obtained at baseline.
  • Participants will be treated with preoperative RT, followed by a planned surgical resection, 4 weeks after the completion of RT.
  • A standard "3 + 3" design will be used to determine the MTD of dose-escalated RT, with 3 dose levels (DL1- 30 Gy delivered in 10 fractions, DL2-36 Gy in 12 fractions, DL3-42 Gy in 14 fractions).
  • Postoperative surveillance imaging studies and laboratory tests will be performed every 3 months in the first 3 years, then every 6 months thereafter in years 4-10. FDG-PET scan will be performed every 6 months postoperatively in the first 3 years, then every year in years 4-10. Additional assessments may be performed if clinically indicated.
03

Conditions studied

  • Adrenocortical Carcinoma (ACC)
  • Recurrent Adrenocortical Carcinoma (ACC)
  • Recurrent Abdominal Adrenocortical Carcinoma (ACC)
  • Carcinoma, Adrenocortical
  • Carcinoma, Adrenal Cortical

Keywords

  • external beam radiation therapy (EBRT)
  • abdominal adrenocortical carcinoma (ACC)
  • preoperative radiation
  • Mitotane
  • Maximum Tolerated Dose (MTD)
  • Surgical Resection
  • in-field intraabdominal progression-free survival (PFS)
  • out-of-field intraabdominal progression-free survival (PFS)
  • DNA damage repair markers
  • oxidative stress response
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Pathological confirmation of ACC by the Laboratory of Pathology, NCI. Note: Confirmation may be done from ; fresh tissue is not required unless otherwise acquired for clinical purposes.
  • by RECISTv1.1. criteria at enrollment
  • Evidence of recurrent ACC amenable to surgical resection that can be performed at NIH Clinical Center (CC)
  • Must be suitable for external beam radiotherapy AND surgery in the opinion of the treating investigator (e.g., based on clinical history and imaging)
  • Participants with ACC outside the area(s) to be exposed to treatments (e.g., liver parenchyma, lung[s], or bone[s]) must have disease that is amendable for a complete resection and/or catheter-based and/or radiation-based ablation.
  • Mitotane therapy- Participants may be receiving mitotane currently, have received it in the past, or never have received mitotane. However, participants will be evaluated in separate cohorts based on mitotane use and, as enrollment is sequential, not all participants may be eligible for the study at all times. Note: Participants with a history of mitotane use may continue on study at the discretion of the treating investigator. Participants will not initiate mitotane on study.
  • Participants must agree to undergo tumor biopsy of easily accessible tumor sites prior to study treatment.
  • Performance Status () 0-2
  • Adequate organ function, including:

    • >= 9.0 gm/dL
    • >= 1,500/mm\^3
    • >= 75,000/mm\^3
    • and ALT \<= 3 x Upper Limit Normal ()
    • \<= 2 x ULN
    • Creatinine within normal institutional limits or >60 mL/min/1.73 m\^2 for participants with creatinine levels above institutional normal calculated using .
  • Individuals of must agree to use an effective method of (hormonal or barrier method of birth control; abstinence) prior to RT and continue until at least 4 months following cytoreduction surgery.
  • Nursing (including breastfeeding) participants must agree to discontinue nursing prior to RT and continue until at least 4 months following cytoreductive surgery.
  • Ability of participant to understand and willingness to sign a written document
  • Participants must agree to co-enroll in tissue collection protocol 09C0242 "Prospective comprehensive molecular analysis of endocrine neoplasms."

Exclusion criteria

EXCLUSION CRITERIA:

  • Primary ACC or suspicious/indeterminate adrenal tumor without pathological confirmation
  • Prior abdominal radiation therapy
  • Participants who have received chemotherapy, immunotherapy, therapy, or radiotherapy treatment within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 .
  • Infection requiring parenteral antibiotics
  • Suspected or proven ACC peritoneal
  • Pre-existing known or suspected radiation sensitivity syndromes
  • Prohibitive condition(s) to diagnostic laparoscopy
  • Participants who have an unacceptable risk for a major surgical procedure such as participants with high risks for major cerebro-cardiovascular (such as those who had doxorubicin exposure as based on screening echocardiogram and ) and pulmonary complications and those with estimated perioperative mortality greater than 15% per ACS NSQIP Surgical Risk calculator.
  • Participants receiving other investigational therapies
  • Participant pregnancy
  • Active systemic infections, coagulation disorders, or other major medical illnesses such as uncontrolled diabetes mellitus, uncontrolled hypertension (persistently grade 2 or worse), active severe cerebro-cardio-pulmonary diseases, and acute major organ dysfunction.
  • Acute intraabdominal conditions such as obstruction or peritonitis at the time of the evaluation or surgery.
  • Evidence at screening of or currently active within 6 months of RT; participants with history of treated brain metastases with intracranial recurrence within 6 months prior to treatment. Note: Participants with any signs or symptoms suggestive of previously undiagnosed brain metastasis at screening or with a history of brain metastasis should receive imaging at screening; otherwise, imaging is not required.
  • -positive participants with CD4 below 200 or who are not on anti-retroviral therapy
  • Participants who have a history of another primary from which the participant has been disease-free for \< 3 years at the time of enrollment.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Preop RT + surgery

    Preoperative RT at escalating doses followed by surgical resection

    Procedure: Surgical resection · Radiation: Preoperative RT

Interventions

  • ProcedureSurgical resection

    Planned surgical resection (all participants) 4 weeks after completion of the preoperative RT

  • RadiationPreoperative RT

    Preoperative RT at escalating doses in daily fractions over approximately 2-3 weeks; 2 weeks (DL1), or 3 weeks (DL2 or DL3) based on assigned Cohort and Dose Level (DL). Cohorts are by mitotane status at enrollment: Cohort 1 (with detectable mitotane levels), Cohort 2 (never had or without detectable mitotane levels), Cohort 3 (either).

06

What researchers measure

Primary outcomes

  1. Determine the maximum tolerated dose (MTD) and safety and toxicity profile of preoperative external beam radiation therapy (RT) with or without standard-of-care mitotane, before surgical resection in participants with resectable recurrent ACC

    Fraction of participants with a dose-limiting toxicity (DLT) will be reported at each dose level

    Time frame: from the start of RT and for 30 days after its completion

Secondary outcomes

  1. Determine the 30-day postoperative complications per Clavien-Dindo classification

    Assessment of 30-day postoperative RT complications determined by Clavien-Dindo classification (frequency and and severity)

    Time frame: baseline, until 30 days after cytoreductive surgery

  2. Determine the objective response of ACC within the radiation treatment field per RECIST criteria

    Objective response determined by RECIST, results as fraction in evaluable participants and by 95% confidence interval of the median

    Time frame: baseline, every 3-6 months after cytoreductive surgery for up to 10 years after surgery

  3. Assess in-field intraabdominal progression-free survival (PFS)

    In-field intraabdominal progression-free survival (PFS) determined by RECIST using the Kaplan-Meier method and by 95% confidence interval of the median

    Time frame: baseline, every 3-6 months after cytoreductive surgery for up to 10 years after surgery

  4. Determine overall survival (OS) through 10 years postoperatively

    Overall survival (OS) up to 10 years postoperatively determined by RECIST using the Kaplan-Meier method and by 95% confidence interval of the median

    Time frame: baseline, every 3-6 months after cytoreductive surgery for up to 10 years after surgery

  5. Assess quality of life measured by Short Form-36 Health Survey version 1.0 (SF-36 V1) questionnaire

    Quality of life (QOL) measured by SF-36 V1 questionnaire evaluated using appropriate paired tests and descriptive results

    Time frame: baseline, 4 weeks after RT, and then 2 weeks, 4 weeks, 6 months and 12 months after surgery

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD recorded will be shared upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data from this study may be requested from other researchers within 10 years after the completion of the primary endpoint by contacting the Principal Investigator.

Access criteria: Data from this study may be requested by contacting the PI.

09

Timeline

39 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Dec 2030, 48 months later.

Start moved 39 times since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 5, 2024
StartEst.
Nov 25, 2026was Sep 2026
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2040
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 29, 2026→Nov 25, 2026
moved 39 times, Sep 25, 2026 – Nov 20, 2026
Show all 39 updates
  1. Nov 20, 2026
    Start date Nov 24, 2026→Nov 25, 2026
  2. Nov 19, 2026
    Start date Nov 23, 2026→Nov 24, 2026
  3. Nov 18, 2026
    Start date Nov 22, 2026→Nov 23, 2026
  4. Nov 17, 2026
    Start date Nov 19, 2026→Nov 22, 2026
  5. Nov 16, 2026
    Start date Nov 18, 2026→Nov 19, 2026
  6. Nov 13, 2026
    Start date Nov 17, 2026→Nov 18, 2026
  7. Nov 12, 2026
    Start date Nov 15, 2026→Nov 17, 2026
  8. Nov 10, 2026
    Start date Nov 12, 2026→Nov 15, 2026
  9. Nov 9, 2026
    Start date Nov 11, 2026→Nov 12, 2026
  10. Nov 6, 2026
    Start date Nov 10, 2026→Nov 11, 2026
  11. Nov 5, 2026
    Start date Nov 9, 2026→Nov 10, 2026
  12. Nov 4, 2026
    Start date Nov 8, 2026→Nov 9, 2026
  13. Nov 3, 2026
    Start date Nov 5, 2026→Nov 8, 2026
  14. Nov 2, 2026
    Start date Nov 4, 2026→Nov 5, 2026
  15. Oct 30, 2026
    Start date Nov 3, 2026→Nov 4, 2026
  16. Oct 29, 2026
    Start date Nov 2, 2026→Nov 3, 2026
  17. Oct 28, 2026
    Start date Nov 1, 2026→Nov 2, 2026
  18. Oct 27, 2026
    Start date Oct 29, 2026→Nov 1, 2026
  19. Oct 26, 2026
    Start date Oct 28, 2026→Oct 29, 2026
  20. Oct 23, 2026
    Start date Oct 27, 2026→Oct 28, 2026
  21. Oct 22, 2026
    Start date Oct 26, 2026→Oct 27, 2026
  22. Oct 21, 2026
    Start date Oct 25, 2026→Oct 26, 2026
  23. Oct 20, 2026
    Start date Oct 22, 2026→Oct 25, 2026
  24. Oct 19, 2026
    Start date Oct 21, 2026→Oct 22, 2026
  25. Oct 16, 2026
    Start date Oct 20, 2026→Oct 21, 2026
  26. Oct 15, 2026
    Start date Oct 19, 2026→Oct 20, 2026
  27. Oct 14, 2026
    Start date Oct 18, 2026→Oct 19, 2026
  28. Oct 13, 2026
    Start date Oct 14, 2026→Oct 18, 2026
  29. Oct 9, 2026
    Start date Oct 13, 2026→Oct 14, 2026
  30. Oct 8, 2026
    Start date Oct 12, 2026→Oct 13, 2026
  31. Oct 7, 2026
    Start date Oct 11, 2026→Oct 12, 2026
  32. Oct 6, 2026
    Start date Oct 8, 2026→Oct 11, 2026
  33. Oct 5, 2026
    Start date Oct 7, 2026→Oct 8, 2026
  34. Oct 2, 2026
    Start date Oct 6, 2026→Oct 7, 2026
  35. Oct 1, 2026
    Start date Oct 5, 2026→Oct 6, 2026
  36. Sep 30, 2026
    Start date Oct 4, 2026→Oct 5, 2026
  37. Sep 29, 2026
    Start date Oct 1, 2026→Oct 4, 2026
  38. Sep 28, 2026
    Start date Sep 30, 2026→Oct 1, 2026
  39. Sep 25, 2026
    Start date Sep 29, 2026→Sep 30, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06487481
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Nov 25, 2026 (estimated)
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2040 (estimated)
Last update
Nov 20, 2026

Study contacts

Kristine J Villaruel
Contact
kristinejoy.villaruel@nih.gov
(240) 858-7033
Naris Nilubol, M.D.
Contact
niluboln@mail.nih.gov
(240) 760-6154
Naris Nilubol, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion